Pazopanib in EWSR1-NFATC2 Translocation-associated Bone Sarcoma
News, Oncoscience
January 12, 2024“Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma.”
BUFFALO, NY- January 12, 2024 – A new case report was recently published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”
Pazopanib, a multi-kinase VEGF inhibitor, is currently FDA approved for advanced renal cell carcinoma and advanced soft tissue sarcoma; but limited evidence exists on its efficacy in bone sarcomas.
In this case report, researchers Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, and Vivek Subbiah from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. The report also reviews the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.
“In brief, this case, in accordance with previously reported evidence, provides proof of activity of pazopanib in EWSR1-NFATC2 positive sarcoma. The report shows that pazopanib when administered in an adjuvant capacity demonstrated its effectiveness in preventing or delaying the progression of additional metastasis. Nevertheless, due to the adjuvant nature of the treatment, it remains uncertain whether this approach would have resulted in tumor shrinkage. Further pre-clinical studies and clinical studies using pazopanib in EWSR1-NFATC2 sarcomas are warranted.”
Read the full paper: DOI: https://doi.org/10.18632/oncoscience.587
Correspondence to: Vivek Subbiah
Email: vivek.subbiah@scri.com
Keywords: pazopanib, precision oncology, sarcoma
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
